— But a modified intent-to-treat analysis showed a noninferior vaccine efficacy rate WASHINGTON -- An investigational Lyme disease vaccine covering six serotypes across four Borrelia species had a vaccine efficacy (VE) rate of over 70%, but it just missed a preset noninferiority threshold,…
After a warm October weekend, 165 Islanders lined up to donate their blood at the Agricultural Hall and Morning Glory Farm for a study on the public health burden of tick-borne conditions, specifically chronic or persisting Lyme disease. A mini-laboratory was…
If you want to know how bad a future tick season will be, it may be more useful to count the number of acorns on the ground than the number of deer in the forest. That’s one of several surprising…
Lyme disease, caused by Borrelia bacteria and transmitted by black-legged ticks, demands vigilant prevention, timely diagnosis, and effective treatment to minimize health and public safety risks. ICT: What are the most effective strategies for preventing Lyme disease during the fall…
(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. Dr. Peter McCullough’s wife was bitten by a tick after a kayak outing near…
Brendan is an experienced journalist who has several years working across news and sport for different organisations, including Derry News, SPORTbible and GRV. When not writing or reporting on sports, Brendan can be seen on the pitch taking part in…
Lyme disease cases in Maine so far this year are tracking slightly ahead of 2025, when the state set a record for the tickborne disease. Megan Porter, health educator with the Maine Center for Disease Control and Prevention, said she can’t…
WASHINGTON — A phase 3 clinical trial revealed that the investigational vaccine candidate — known as LB6V — showed more than 70% efficacy against confirmed Lyme disease, according to results presented at IDWeek. But, in the end, the drug failed to hit its primary endpoint. LB6V has…
HealthBio, Inc., a biotechnology company developing novel immune-reset therapies for inflammatory disease, today announced the initiation of its multi-center, randomized, double-blind, placebo-controlled clinical trial (HBT-002; IND185316) evaluating its lead compound Inflamexa™, in adults with post-treatment Lyme disease syndrome (PTLDS). Oops, something…
Lyme disease cases in Maine so far this year are tracking slightly ahead of 2025, when the state set a record for the tickborne disease. Megan Porter, health educator with the Maine Center for Disease Control and Prevention, said she can’t…
Lyme disease and other tick-borne illness, including babesiosis, Powassan virus and spotted fever: cases, vaccines and prevention.
An article joins this feed when it matches these terms. Each one is also a search of its own.